Evidence map›Paper›PMID 29760129›Full record

ArticleAntimicrobial agents and chemotherapy2018

Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir.

Emanuele Focà, Andrea Calcagno, Andrea Bonito, Jessica Cusato, Elisabetta Domenighini, Antonio D'Avolio, Eugenia Quiros Roldan, Laura Trentini, Filippo Castelnuovo, Giovanni Di Perri and 2 more

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Emanuele Focà *Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, University of Brescia and Spedali Civili General Hospital, Brescia, Italy Emanuele.foca@unibs.it.ORCID 0000-0003-4395-5379
Andrea Calcagno *Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Turin, Italy.
Andrea BonitoUnit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, University of Brescia and Spedali Civili General Hospital, Brescia, Italy.
Jessica CusatoUnit of Infectious Diseases, Department of Medical Sciences, University of Torino, Turin, Italy.
Elisabetta DomenighiniUnit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, University of Brescia and Spedali Civili General Hospital, Brescia, Italy.
Antonio D'AvolioUnit of Infectious Diseases, Department of Medical Sciences, University of Torino, Turin, Italy.ORCID 0000-0002-1321-4126
Eugenia Quiros RoldanUnit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, University of Brescia and Spedali Civili General Hospital, Brescia, Italy.
Laura TrentiniUnit of Infectious Diseases, Department of Medical Sciences, University of Torino, Turin, Italy.
Filippo CastelnuovoUnit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, University of Brescia and Spedali Civili General Hospital, Brescia, Italy.
Giovanni Di PerriUnit of Infectious Diseases, Department of Medical Sciences, University of Torino, Turin, Italy.
Francesco CastelliUnit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, University of Brescia and Spedali Civili General Hospital, Brescia, Italy.
Stefano BonoraUnit of Infectious Diseases, Department of Medical Sciences, University of Torino, Turin, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atazanavir-ritonavir concentrations change over time during pregnancy in HIV-positive patients; the impact of genetic variants is unknown. Twenty patients were enrolled in this study; plasma and intracellular concentrations of antiretrovirals were measured, in addition to single-nucleotide polymorphisms in transport-related genes. Linear logistic regression showed that genetic variants in organic-anion-transporter-1B1- and pregnane-X-receptor-encoding genes affected third-trimester atazanavir exposure. In this prospective study, genetic variants partially explained the observed interpatient variability in third-trimester exposure to antiretrovirals.

Indexed as

AdultAtazanavir SulfateDrug Administration ScheduleDrug Therapy, CombinationFemaleHIV InfectionsHIV Protease InhibitorsHumansLiver-Specific Organic Anion Transporter 1Polymorphism, Single NucleotidePregnancyPregnancy Complications, InfectiousPregnancy Trimester, ThirdPregnane X ReceptorProspective StudiesRitonavirAtazanavir SulfateHIV Protease InhibitorsLiver-Specific Organic Anion Transporter 1NR1I2 protein, humanPregnane X ReceptorRitonavirSLCO1B1 protein, humanantiretroviral agentsantiviral pharmacologyHIV

Identifiers

PMID29760129
PMCPMC6021630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.